The level of glial neurotrophic factor in blood plasma depending on the stage of Parkinson’s disease
Objective: To study the level of glial neurotrophic disease in blood plasma in patients with Parkinson's disease (PD) depending on the stage Background: Parkinson's disease…The Role Imposed by The High-Mobility Group Box 1 (HMGB1) Protein in MPTP-Induced Zebrafish Model of Parkinson’s Disease
Objective: This study aims to investigate the role of HMGB1 protein in mediating neuroinflammatory-induced parkinsonian movement disorder of the MPTP-induced zebrafish model of Parkinson's disease…Tissue-engineered nigrostriatal pathway to rebuild dopaminergic axons in Parkinson’s disease based on clinical design criteria
Objective: To create a tissue-engineered construct with the dopaminergic (DA) cell numbers, axon lengths, and functionality required to reconstruct the human nigrostriatal pathway (NSP). Background:…Auxilin knockout mice: a model for Parkinsonism with dopamine dysregulation and synucleinopathy
Objective: To evaluate the role of auxilin in the pathogenesis of Parkinson’s disease (PD). Background: Auxilin or DNAJC6, a brain-specific co-chaperone plays central role in…Effects of exosomes devised from dopaminergic neurons overexpressing α-synuclein on autophagy and inflammation in microglia
Objective: The aim of this study was to investigate whether the exosomes secreted by dopaminergic neurons over-expressing α-synuclein could regulate the inflammation of microglia via…L-DOPA treatment in N2a cells stimulates neuromelanin biosynthesis: Using a novel in vitro model to examine the effect of iron and light on neuromelanin production
Objective: Naturally-occuring quantities of in vivo neuromelanin (NM) are low, and the collection of NM from tissue involves laborious extraction and isolation. Thus, in vitro…The Influence of 3-Phenoxybenzoic Acid in Dopaminergic Degeneration
Objective: 3-phenoxybenzoic acid (3-PBA) is a metabolite of Fenpropathrin (FEN). The emphasis of this paper is on the relationship between 3-PBA and Dopaminergic Degeneration. Background:…Effects of Long-Term Treatment with Fluvoxamine on Non-Motor Symptoms and Neurogenesis in an Early Post-Natal Stress Rat Model of Parkinson’s Disease
Objective: To look at the long-term effects of Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), and its neuroprotection potential in a rat model of Parkinson’s…Parkinson’s disease and osteocalcin pilot study: Is there a protective role of bone in neurodegeneration?
Objective: To characterize the relationship between the bone-derived hormone osteocalcin (OCN) and Parkinson’s disease (PD) in humans, and explore sex and treatment differences. Background: The…Effects of a next-generation neurotrophic compound in a toxin model of Parkinson’s disease
Objective: Investigate the effects of a peripherally administered novel neurotrophic compound, CMx01a, in 6-hydroxydopamine rat model of Parkinson’s disease. Background: Neurotrophic factors are promising drug…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 15
- Next Page »